Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,664 JPY | +1.87% | +1.93% | +1.15% |
25/04 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
08/04 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Casinos & Gaming
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.15% | 2.32B | D+ | ||
+11.20% | 8.25B | C | ||
-25.64% | 703M | B- | ||
+29.76% | 358M | - | - | |
+5.69% | 349M | C- | ||
+3.88% | 327M | - | - | |
-7.63% | 270M | D+ | ||
+15.54% | 182M | - | - | |
+26.63% | 99.29M | - | - | |
-28.33% | 63.25M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 6417 Stock
- Ratings Sankyo Co., Ltd.